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The Next Frontier*William W. O’Neill, MD,y Brian P. O’Neill, MDzT he pioneering work of Dr. Alan Cribier (1) in2002 ushered in a new era for the treatmentof valvular heart disease. In the past decade,
transcatheter aortic valve replacement (TAVR) has
gone from a difﬁcult, moderately successful proce-
dure (2,3) to a widely adopted intervention that rivals
surgical AVR (4,5). Because untreated critical aortic
stenosis (AS) is such a lethal condition, a survival
advantage of TAVR to the medical therapy was
accomplished with 1-year follow-up (6).
The success of TAVR has stimulated attempts at
transcatheter mitral valve replacement (TMVR) for
percutaneous treatment of mitral regurgitation (MR).
This has proven to be far more complex than TAVR.
The “D” shape of the mitral annulus, the large width
of the oriﬁce, and the potential interaction with the
aortic outﬂow tract have been challenging. Currently,
ﬁrst-in-human testing has begun, and this year will
bring forth the ﬁrst moderately sized trials of trans-
catheter TMVR (7). Alternately, attempts at trans-
catheter mitral valve repair have occurred. One such
device (MitraClip, Abbott Vascular, Santa Rosa, Cali-
fornia) recently received U.S. Food and Drug Admin-
istration approval (8). Mitral annulus plication with
another device (Mitralign, Tewksbury, Massachu-
setts) is currently being tested in Europe. This device
lacks the precise visualization required to place
the pledgets in proper anatomic location. The ad-
vances in three-dimensional (3D) transesophageal*Editorials published in the Journal of the American College of Cardiology
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problem. A recent trial in Europe investigated the
use of the Mitralign device for functional MR in 61
patients, and follow-up data are being collected.
Apart from the daunting technical challenges,
proof of efﬁcacy for interventions in chronic,
moderate, or severe MR is far more difﬁcult than
critical AS. Mechanical reduction or elimination of
regurgitation alone is insufﬁcient. Mortality trials
will need to study hundreds if not thousands of
patients and conduct at least 5 years of follow-up
to show beneﬁt. Safety endpoints, such as symp-
tom status and heart failure readmissions, are
subject to the placebo effect, and skeptics may de-
mand sham procedures with strict double blinding.
Despite these challenges, there is such a large pool
of high-risk/inoperable patients with severe MR that
within 10 years, it is likely that effective trans-
catheter therapy will emerge. With transcatheter
aortic valve intervention proven and mitral valve
intervention emerging, attention will soon turn to
the third heart valve that malfunctions in adults:
the tricuspid valve.
Tricuspid regurgitation (TR) remains an under-
treated problem with substantial morbidity. In the
United States alone, <1% of patients with moderate or
severe TR undergo surgery annually (9). This is
despite a 1-year mortality rate of 36.1%, which has
been reported in a Veterans Affairs retrospective
study of patients with severe TR (10). For those pa-
tients who undergo surgery, recurrence of moderate
or severe TR can be as high as 60% at 5 years (11).
Therefore, it is not surprising that only 16% of
patients with isolated severe TR underwent surgery
at 5 years in a recent study (12). Currently, trans-
catheter interventions for tricuspid valve disease
have been restricted primarily to patients with
a degenerating bioprosthesis, with mixed results
(13,14). The mechanical and clinical challenges of
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as those of severe MR. First, cardiologists do not
attempt to quantify the severity of TR during right
heart catheterization. Second, imaging with contrast
ventriculography or echocardiography has not been
standardized and widely promulgated. Standardized
methods of quantifying improvement of TR will be
required for testing efﬁcacy of interventions. Finally,
isolating the impact of TR in the setting of pulmonary
hypertension, atrial ﬁbrillation, and left heart pa-
thology is problematic. Despite these challenges, our
aging population, the increasing prevalence of atrial
ﬁbrillation, the increase in iatrogenic TR from trans-
venous pacemaker leads, and the likely increase in
life expectancy of patients with effectively treated AS
and MR will mandate development of transcatheter
therapy. Schofer et al. (15) began this long journey
with a ﬁrst step.SEE PAGE 1190In this issue of the Journal, the authors present
the ﬁrst-in-human experience with percutaneous
tricuspid valve repair for functional TR (Mitralign
system). The procedure was performed with the use
of an 8-F deﬂectable catheter that was advanced
into the right ventricle through the internal jugular
vein. With the use of 3D TEE guidance, previously
a limitation to accurately image the tricuspid valve,
a radiofrequency wire was advanced through the
tricuspid valve annulus that allowed the placement
of two pledgeted sutures around the posterior leaﬂet.
Through direct plication of these sutures with a
locking device, the authors performed a modiﬁed Kay
bicuspidalization of the tricuspid valve. In-hospital
results were favorable, with dramatic reductions in
right atrial pressures and annular area as measured
by means of TEE, with the patient being discharged
from the hospital within 5 days (15).
Although off-label use of TAVR technology has
been applied to the failing bioprosthesis in thetricuspid valve position (14), percutaneous therapies
for direct native tricuspid valve intervention are
currently lacking; this is due in part to the lack of a
rigid landing zone for valve deployment such as
in AS, as well as the variety of annular dimensions
that may occur in severe TR. This has recently led to
some experience with heterotopic placement of
transcatheter aortic valves in the inferior vena cava
in those patients with refractory ascites and lower-
extremity edema (16,17). Short-term results demon-
strating reduction in ascites, hepatic congestion,
and peripheral edema are encouraging. Long-
term follow-up is needed. Finally, investigators are
currently exploring the transjugular use of the
MitralClip system to attempt leaﬂet tethering and
decrease functional TR (B. Maini, personal commu-
nication, January 2015).
While we enthusiastically wait for effective trans-
catheter therapy, an increasing population of patients
with severe TR exists. In our experience, clinicians
may fail to appreciate that severe TR causes portal
hypertension and bowel edema, which make oral
furosemide therapy ineffective (18). Addition of
bumetanide in twice-daily doses of 2 to 10 mg can
effectively decrease peripheral edema. Simple mea-
sures, such as insisting that patients lie with legs
elevated above the heart level, also can be helpful.
Finally, recognition that transvenous procedures can
cause severe TR in up to 30% of implants may prompt
our electrophysiologist colleagues to develop better
implant techniques to avoid severe TR. Severe TR is
ﬁnally getting the recognition that it deserves, and a
once-ignored valve pathology may succumb to
transcatheter therapy.
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